Crossmark

Potassium-competitive acid blocker has more negative impacts on clinical outcomes in patients with non-small cell lung cancer treated with checkpoint inhibitors than those of proton pump inhibitors

Crossref DOI link: https://doi.org/10.1007/s10147-025-02805-2

Published Online: 2025-06-12

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Takahashi, Masaya

Nakatsukasa, Hitomi

Shibano, Masahito

Ishigami, Yusuke

Oka, Takako

Tani, Yoko

Kawaguchi, Tomoya

Nakamura, Yasutaka

Kaneda, Hiroyasu https://orcid.org/0000-0002-7696-2391
License Information

Text and Data Mining valid from 2025-06-12

Version of Record valid from 2025-06-12
More Information

Article History

Received: 3 February 2025

Accepted: 27 May 2025

First Online: 12 June 2025

Declarations

:

: Dr. Kaneda has received lecture fees from Chugai, MSD, Ono pharmaceutical, and Bristol-Myers Squibb. All other authors declare that they have no conflicts of interest.

: This study was approved by the Human Subjects Review Committee of Osaka Metropolitan University (Approval no. 2023–003). The need for informed consent was waived by the Human Subjects Review Committee at each hospital, and the participants were free to opt out if they no longer wished to participate.

: The need for informed consent was waived by the Human Subjects Review Committee of our hospital, and the participants were free to opt out if they no longer wished to participate.

: Not applicable.

Document is current

Any future updates will be listed below